ProShares UltraShort NASDAQ Biotechnology
10 hedge funds and large institutions have $3.06M invested in ProShares UltraShort NASDAQ Biotechnology in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
25% more funds holding
Funds holding: 8 → 10 (+2)
0.41% more ownership
Funds ownership: 14.11% → 14.51% (+0.41%)
13% less capital invested
Capital invested by funds: $3.51M → $3.06M (-$445K)
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$457K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$384K |
| 3 |
Morgan Stanley
New York
|
+$10.5K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$5.41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$695K |
| 2 |
VF
Virtu Financial
New York
|
-$319K |
| 3 |
WP
WealthSource Partners
San Luis Obispo,
California
|
-$265K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$48.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$28.1K |
BIS Hedge Fund Activity: Q2 2019 in Review
10 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q2 2019, worth a combined $3.06M — down 13% from $3.51M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BIS positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 5 trimmed.
The largest buyer was Bellevue Group, opening a new position worth an estimated $457K. The largest seller was Tower Research Capital (TRC), cutting an estimated $695K.
- 10 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q2 2019, up from 8 in Q1 2019.
- Funds reported $3.06M of ProShares UltraShort NASDAQ Biotechnology stock for Q2 2019, down 13% quarter-over-quarter.
- 3 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q2 2019 and 1 closed out, a net change of +2 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q2 2019 was Bellevue Group, an estimated $457K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q2 2019 was Tower Research Capital (TRC), an estimated $695K sold.
Based on aggregated 13F filings for Q2 2019.